Future in vivo studies in an animal model of obesity are required to delineate the potential benefit of altering the CCR4/CCL17/CCL22 signalling in vivo and assess the therapeutic window of CCR4 inhibition. Here, CCL22 is linked to obesity due to melanocortin 4 receptor deficiency.